Find support groups, events and resources near you

PCRP - The Prostate Cancer Research Program (PDF)

Prostate Cancer Research Program Flier

Download the PDF

The Prostate Cancer Research Program (PCRP) began in 1997 as a part of the Congressionally Directed Medical Research Programs, or CDMRP. Created by Congress in 1992 and administered by the Department of Defense, CDMRP programs advance biomedical research, with a particular focus on applied research that supports the greatest needs of the disease community and U.S. service members.

Prostate cancer is a real threat to men who serve in the U.S. military, with 1 in 5 Veterans and active-duty servicemembers being diagnosed with the disease in their life time.

The PCRP is dedicated to supporting high-risk, high-reward research with near-term clinical application to eradicate prostate cancer deaths and promote groundbreaking development of new tests and treatments. ZERO supports increasing funding for the PCRP from $110M to $120M for Fiscal Year 2025.

A key component of the PCRP is the Consumer Reviewer Panel, comprised of patients, providers, clinicians, and caregivers who act as lay experts on prostate cancer, bringing their lived experiences and perspectives to the evaluation of research grant proposals. This helps ensure that the research conducted will make a meaningful difference in the lives of prostate cancer patients.

The PCRP has contributed to developing 7 new treatments in the last decade. These include multiple therapies for metastatic prostate cancer that no longer respond to other treatments. PCRP investment has also supported the development of a new test that helps identify aggressive prostate cancers to allow patients and their doctors to better determine the best treatment method.

The PCRP is a critical component of the fight against prostate cancer and the country's cancer research enterprise. As a Veteran, prostate cancer survivor, and prior PCRP reviewer, I've seen the tremendous work that the program does for the prostate cancer community as a whole and the specific value to military servicemembers and Veterans like myself. In fact, I credit several therapeutics developed with PCRP funding as the reason why I'm alive today after a stage 4 cancer diagnosis almost ten years ago.

— Col. Paul Taylor, U.S. Army, Retired